| Literature DB >> 30954684 |
Nabeela Dulull1, Faith Kwa2, Narin Osman3, Uma Rai1, Bilal Shaikh1, Thilini R Thrimawithana4.
Abstract
Diabetic retinopathy (DR) is a microvascular complication of diabetes and is the leading cause of vision loss in people with diabetes. The current treatments do not target early stages of disease or impede disease progression. Therefore, the identification of new therapeutic targets, the development of novel therapies targeting early stages of the disease and accurate models that simulate pathological characteristics of this disorder are crucial. This review provides an overview of the pathological mechanisms underlying the development of DR, highlighting the recent advances in current and emerging treatments for DR.Entities:
Mesh:
Year: 2019 PMID: 30954684 DOI: 10.1016/j.drudis.2019.03.028
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851